Prime Medicine
Yi Pu has extensive work experience in the field of scientific research and academia. They began their career as a Teaching Assistant at Boston University in 2009 and worked in this role until 2011. Following this, Yi Pu served as a Research Assistant at Boston University School of Medicine from 2011 to 2016. In 2015, they had a brief cooperative position at Biogen.
Yi Pu then joined Biogen as a Scientist I in 2016 and was promoted to Scientist II in 2019. They held these positions until 2021. During their time at Biogen, they gained valuable experience and expertise in scientific research and development.
In 2021, Yi Pu transitioned to Prime Medicine, Inc. as a Senior Scientist. They currently hold this position. Additionally, they have recently taken on the role of Group Head at Prime Medicine as of November 2022.
Overall, Yi Pu's work experience includes teaching, research, and leadership roles in both academia and industry, making them a well-rounded and experienced professional in the field of scientific research.
Yi Pu earned a Bachelor of Engineering (BEng) degree in Materials Science and Engineering from Beihang University. After completing their undergraduate education, Yi Pu attended Boston University, where they obtained a Master of Arts (MA) degree in Chemistry from 2009 to 2011. They continued their studies at Boston University and completed a Doctor of Philosophy (PhD) degree in Chemistry from 2011 to 2016.
This person is not in any teams
This person is not in any offices
Prime Medicine
4 followers
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.